ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of SEBI's Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, we furnish herewith the Secretarial Compliance Report, for the year ended March 31, 2022. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board recommends Final Dividend
AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2022, inter alia, has recommended Final Dividend of Rs. 8/- per equity share for the financial year 2021-22. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Thursday, May 26, 2022
The Board of Directors of the Company at their meeting held today i.e., May 26, 2022, has inter-alia: 1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2022. The said Audited Financial Results together with the Audit report of the Statutory Auditors dated May 26, 2022 are enclosed herewith. 2. Recommended Final Dividend of Rs. 8/- per equity share for the financial year 2021-22 We also confirm that the Auditor's Report is with unmodified opinion in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2022. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board to consider FY22 results & Final Dividend on May 26, 2022
AstraZeneca Pharma India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2022, inter alia:1. To consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022.2. To recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022.Further, the 'Trading Window' remains closed for all Designated Persons, from March 16, 2022 to May 28, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday, May 26, 2022
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Thursday, May 26, 2022 inter alia: a. To consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022 b. To recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from March 16, 2022 to May 28, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated May 3, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
AstraZeneca Covid booster shot effective against severe disease: UK study
The third dose of AstraZeneca COVID vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer, according to a study in the UK